Addex Therapeutics Ltd (SWX:ADXN)

Market Cap	5.13M -10.4%
Revenue (ttm)	109.50K -55.5%
Net Income	-6.97M
EPS	-0.06
Shares Out	119.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,500
Open	0.0430
Previous Close	0.0430
Day's Range	0.0430 - 0.0430
52-Week Range	0.0336 - 0.0850
Beta	1.99
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 15, 2026

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, ad...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 3
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: ADXN

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 13, 2026

Data Sources Report a data error